查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015006

黑色素瘤治療市場：按治療方法、作用機制、給藥途徑和分銷管道分類的全球市場預測，2026-2032年

Melanoma Drug Market by Therapy Type, Mechanism Of Action, Route Of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，黑色素瘤治療市場價值將達到 25.1 億美元，到 2026 年將成長至 27.3 億美元，到 2032 年將達到 47.5 億美元，複合年成長率為 9.54%。

主要市場統計數據
基準年 2025 25.1億美元
預計年份：2026年 27.3億美元
預測年份 2032 47.5億美元
複合年成長率 (%) 9.54%

對近期科學突破和治療方法創新如何重塑黑色素瘤治療的治療決策、政策和相關人員優先事項進行策略性概述。

在免疫腫瘤學、精準標靶治療以及涵蓋門診和住院治療的不斷發展的診療路徑的推動下，黑色素瘤的臨床和商業性格局正在發生巨大變化。新的治療方法正在改變治療模式，使其從傳統的細胞毒性療法轉向基於生物學的干涉措施，例如調節免疫系統或抑制特定的癌症基因驅動因子。因此，臨床醫生、保險公司和製藥公司面臨著更複雜的決策環境，需要在療效、安全性、耐受性和實際應用等因素與藥物可近性和報銷趨勢之間取得平衡。

免疫腫瘤學、標靶治療、給藥途徑和診斷技術的突破如何從根本上改變黑色素瘤治療的臨床路徑、獲取途徑和商業模式。

黑色素瘤的治療模式正從單一細胞毒性藥物治療轉向免疫調節和分子標靶治療相結合的綜合療法，這從根本上改變了臨床路徑和商業模式。免疫療法，尤其是查核點抑制劑，正在重新定義人們對持續緩解和長期存活的預期，促使患者監測、毒性管理和倖存者照護計畫發生改變。同時，針對BRAF和MEK等可治療突變的精準標靶治療，能夠使生物標記陽性患者的腫瘤得到快速控制，從而開闢聯合治療策略和抗藥性管理的新領域。

評估不斷變化的貿易措施及其對美國癌症治療供應鏈的韌性、價格壓力和獲取管道的系統性影響

貿易政策趨勢，包括關稅措施和進口限制，對醫藥生態系統產生顯著而多方面的影響，波及供應鏈、採購決策以及先進治療方法的成本結構。在癌症治療領域，高度複雜的生物製藥和特化小分子化合物的生產依賴全球供應鍊網路，關稅可能造成上游工程成本壓力，進而波及整個生產、分銷和採購流程。這些壓力可能促使製造商重新評估其區域製造地、供應鏈冗餘和籌資策略，以降低潛在關稅變化帶來的風險。

基於細分市場的詳細見解解釋了治療方法類型、分子機制、劑型和分銷管道如何綜合決定臨床引進和商業性成功。

從細分觀點，我們可以發現治療方法、作用機制、給藥途徑和分銷管道如何共同塑造臨床應用和商業性化過程。不同治療類別之間有顯著差異。雖然傳統的細胞毒性化學療法在某些情況下仍然發揮作用，但免疫療法在許多治療階段都至關重要，並且能夠為部分患者帶來持續的療效。基於分子譜的標靶治療在生物標記定義的患者群體中顯示出較高的初始反應率，從而改變了治療方案的時機和順序。這些治療方法的差異要求我們設計獨特的臨床試驗方案、安全監測框架，並進行真實世界數據（REW）研究，以證實其長期療效。

比較主要全球市場中影響黑色素瘤治療方法普及和取得途徑的區域趨勢和醫療保健基礎設施因素。

黑色素瘤治療的區域趨勢反映了管理體制、醫療基礎設施、報銷模式和診斷能力方面的差異，所有這些因素都影響著治療方法的推廣速度和模式。在美洲，先進治療方法的集中核准、活躍的臨床試驗以及整合的專科醫療網路，都促進了新型免疫療法和標靶治療的早期應用。同時，支付方的審查和基於價值的合約正日益影響藥物在推廣清單上的排名和取得順序。此外，該地區醫療系統的整合以及專科藥房的成長正在影響藥物分銷策略和患者支援模式，從而推動了整合式醫療路徑的形成。

創新者、生物製藥製造商和策略合作夥伴之間的競爭，強調黑色素瘤治療中證據的深度、供應鏈的韌性和診斷整合。

黑色素瘤治療領域的競爭優勢取決於臨床差異化、證據深度、穩健的生產和供應鏈以及策略夥伴關係關係。主要企業正大力投資研發聯合治療，將免疫查核點抑制劑與標靶治療療法或輔助性治療相結合，旨在延長療效持續時間並控制毒性。涵蓋靜脈注射免疫療法和口服標靶治療的產品系列，在滿足不同患者群體和治療方案的需求方面具有戰略優勢，而整合的伴隨診斷項目則增強了企業與生物標記定義的特定患者群體建立聯繫的能力。

為製藥公司和相關人員制定可操作的策略重點，以協調證據產生、供應彈性和商業化，從而改善藥物可近性並提供長期治療價值。

行業領導企業應採取多管齊下的方法，透過將臨床開發與支付方的證據需求相匹配、增強供應韌性以及最佳化上市時間，最大限度地提高患者可及性和治療效果。首先，企業必須優先考慮與支付方和衛生技術評估機構進行早期且持續的合作，以確保臨床試驗終點、生活品質 (QOL) 指標和真實世界數據 (RWE) 計劃符合報銷預期。將衛生經濟學和結果研究融入開發項目有助於從核准到常規臨床應用的平穩過渡。

採用全面透明的調查方法，結合與專家的直接訪談、監管和臨床文獻的整合以及實際情境分析，以確保獲得可操作的見解。

本報告的研究結果基於結構化的多方面調查方法，該方法整合了對關鍵相關人員的訪談、二手文獻、監管申報文件以及定性綜合分析，從而確保了研究結果的穩健性和相關性。主要資訊來源包括與臨床醫生、政策制定者、保險公司和行業領袖的討論，這些討論反映了不斷發展的臨床實踐、報銷趨勢和實際營運情況。除訪談外，我們還透過仔細審查監管核准、臨床試驗論文、指導文件和診斷檢驗報告，全面檢驗了治療和機制的見解。

本概要重點闡述了科學創新、政策壓力和營運準備三者之間的相互作用。這些因素將決定未來黑色素瘤治療的療效和患者就醫機會。

總之，黑色素瘤治療範式正邁入一個以生物學精準性、免疫調節和日益複雜的給藥方案為特徵的新時代。治療創新在拓展患者選擇的同時，也催生了更精細的決策框架，該框架需整合分子診斷、毒性管理和長期存活規劃。同時，貿易政策和供應鏈趨勢的變化等外部因素凸顯了營運韌性和早期與支付方溝通的重要性，以確保患者能夠獲得治療並維持治療的連續性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 黑色素瘤治療市場（依治療方法分類）

  • 化療
  • 免疫療法
  • 分子標靶治療

第9章 依作用機轉分類的黑色素瘤治療市場

  • BRAF抑制劑
  • 查核點抑制劑
  • MEK抑制劑

第10章：黑色素瘤治療市場：依給藥途徑分類

  • 靜脈
  • 口服

第11章 黑色素瘤治療市場：依通路分類

  • 醫院藥房
  • 零售藥房

第12章 黑色素瘤治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 黑色素瘤治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 黑色素瘤治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國黑色素瘤治療市場

第16章：中國黑色素瘤治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • BioNTech SE
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-0363DFE03682

The Melanoma Drug Market was valued at USD 2.51 billion in 2025 and is projected to grow to USD 2.73 billion in 2026, with a CAGR of 9.54%, reaching USD 4.75 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.51 billion
Estimated Year [2026] USD 2.73 billion
Forecast Year [2032] USD 4.75 billion
CAGR (%) 9.54%

A strategic overview of how recent scientific breakthroughs and delivery innovations are reshaping therapeutic decision-making, policy, and stakeholder priorities in melanoma care

The clinical and commercial landscape for melanoma has undergone profound change driven by advances in immuno-oncology, precision-targeted agents, and evolving care pathways that span outpatient and inpatient settings. New therapeutic modalities have shifted treatment paradigms away from traditional cytotoxic approaches and toward biologically informed interventions that modulate the immune system or inhibit specific oncogenic drivers. As a result, clinicians, payers, and manufacturers face a more complex decision environment in which efficacy, safety, tolerability, and real-world delivery considerations must be balanced against access and reimbursement dynamics.

In parallel, regulatory frameworks have adapted to accelerated approval pathways, companion diagnostics, and post-marketing evidence commitments, raising the bar for robust clinical development plans and lifecycle strategies. These regulatory shifts intersect with changing patient expectations and care delivery models, including greater use of oral targeted agents that enable outpatient management and checkpoint inhibitors that may require infusion infrastructure and multidisciplinary coordination. Consequently, stakeholders must integrate clinical evidence, health economics, and operational readiness into coherent adoption strategies.

Looking ahead, the ability to translate mechanistic innovation into durable clinical benefit will hinge on optimized patient selection, sequencing of therapies, and combination regimens informed by molecular and immune biomarkers. This introduction sets the stage for an in-depth analysis of transformative shifts, trade policy impacts, segmentation insights, regional dynamics, competitive positioning, recommended actions for industry leaders, and the rigorous methods used to assemble the report's findings.

How breakthroughs in immuno-oncology, targeted agents, administration routes, and diagnostics are fundamentally transforming clinical pathways, access, and commercial models in melanoma treatment

The therapeutic landscape for melanoma has shifted from single-agent cytotoxic treatments to integrated approaches that exploit immune modulation and molecular targeting, fundamentally altering clinical pathways and commercial models. Immunotherapies, particularly checkpoint inhibitors, have redefined expectations for durable responses and long-term survivorship, prompting changes in patient monitoring, toxicity management, and survivorship care planning. At the same time, precision-targeted therapies directed at actionable mutations such as BRAF and MEK have enabled rapid tumor control for biomarker-positive patients, creating new frontiers for combination strategies and resistance management.

Concomitantly, the evolution of route of administration preferences is meaningful: oral targeted agents expand outpatient treatment possibilities and reduce infusion resource burdens, whereas intravenous immune agents continue to necessitate infusion capacity and coordinated multidisciplinary care. Distribution and channel dynamics have adapted to these clinical realities, with hospital pharmacies maintaining a central role for infusion-based regimens while retail pharmacies and specialty distributors support adherence and outpatient continuity for oral therapies.

Technology and diagnostics constitute another transformative axis. Wider adoption of next-generation sequencing and validated biomarkers enhances patient stratification and therapeutic sequencing, while advances in digital health tools support toxicity surveillance, adherence monitoring, and decentralized clinical trial models. Taken together, these shifts demand integrated strategies across clinical development, market access, and supply chain planning to ensure that innovation translates into improved outcomes at scale.

Assessment of evolving trade measures and their systemic implications for supply chain resilience, pricing pressures, and access pathways for oncology therapies in the United States

Trade policy developments, including tariff measures and import regulations, have a clear and multifaceted effect on the pharmaceutical ecosystem, influencing supply chains, sourcing decisions, and the cost structure of advanced therapies. In the context of oncology, where high-complexity biologics and specialized small molecules are manufactured through globalized supply networks, tariffs can create upstream cost pressures that ripple through production, distribution, and procurement processes. These pressures may incentivize manufacturers to re-examine regional manufacturing footprints, supply redundancy, and sourcing strategies to mitigate exposure to potential tariff volatility.

Because many oncology products require cold-chain logistics, sterile manufacturing environments, and tightly controlled quality systems, changes in trade costs can complicate logistics planning and extend lead times for critical supplies. Payers and health systems may respond by seeking price concessions, altering formulary placements, or emphasizing value-based contracting to preserve access while managing incremental cost burdens. For developers, heightened tariff-related uncertainty can influence decisions about clinical trial site selection and timing for regulatory submissions where supply continuity is paramount.

At the policy level, engagement between stakeholders and trade authorities becomes more salient, with coordinated advocacy focused on recognizing the unique lifecycle and societal value of oncology medicines. Industry leaders may accelerate investment in near-shore production, dual-sourcing agreements, and inventory strategies to build resilience. In clinical practice, the net effect of tariff-induced cost pressures could manifest as tighter budgetary constraints that affect adoption timing, access pathways, and the relative attractiveness of oral versus intravenous administration when total cost of care considerations are emphasized.

Deep segmentation-driven insights explaining how therapy class, molecular mechanism, administration format, and distribution channels collectively dictate clinical adoption and commercial execution

A segmentation-aware perspective illuminates how therapy modality, mechanism, administration route, and distribution channel combine to shape clinical adoption patterns and commercial execution. Therapeutic categories diverge significantly: traditional cytotoxic chemotherapy retains a role in specific scenarios, while immunotherapy has become a backbone for many stages of care, offering durable responses for a subset of patients. Targeted therapy, informed by molecular profiling, offers high initial response rates for biomarker-defined populations, altering the timing and sequencing of treatment lines. These modality differences require distinct clinical trial designs, safety monitoring frameworks, and real-world evidence efforts to demonstrate long-term benefit.

Delving into mechanism of action, inhibitors targeting oncogenic drivers such as BRAF and companion MEK inhibitors are most relevant where validated mutations are present, enabling precision medicine approaches that prioritize genetic testing and rapid initiation of oral agents. Checkpoint inhibitors, encompassing both CTLA-4 modulators and PD-1 pathway antagonists, operate through immune activation and thus carry distinct toxicity profiles and monitoring needs; they also open opportunities for durable remission when treatment is optimally sequenced or combined. Understanding these mechanistic distinctions is essential for designing payer dossiers and for identifying patient cohorts most likely to benefit.

Route of administration further differentiates care models: intravenous therapies necessitate infusion capacity, specialized nursing, and in-clinic monitoring, concentrating demand within hospital-based settings and specialty infusion centers. Conversely, oral agents shift treatment into ambulatory and home settings, increasing the importance of outpatient pharmacy partnerships, adherence programs, and remote monitoring solutions. Distribution channels mirror these demands, with hospital pharmacies central to inpatient and infusion-dependent regimens while retail pharmacies and specialty pharmacy networks are increasingly pivotal for dispensing oral targeted therapies and supporting adherence interventions.

Comparative regional dynamics and healthcare infrastructure factors shaping the differential adoption and access pathways for melanoma therapies across key global markets

Regional dynamics in melanoma therapeutics reflect differences in regulatory regimes, healthcare infrastructure, reimbursement paradigms, and diagnostic capacity, all of which shape the pace and pattern of adoption. In the Americas, a concentration of advanced therapeutic approvals, robust clinical trial activity, and integrated specialty care networks supports early uptake of novel immunotherapies and targeted agents, while payer scrutiny and value-based contracting increasingly influence formulary positioning and access sequencing. Health system consolidation and specialty pharmacy growth in this region also affect distribution strategies and patient support models, promoting integrated care pathways.

In Europe, the Middle East & Africa, diverse regulatory frameworks and heterogeneous healthcare financing models create a mosaic of access conditions. Regulatory harmonization efforts and centralized assessment bodies can streamline cross-border approvals in some markets, yet variations in diagnostic capacity and reimbursement thresholds influence local adoption. Middle Eastern markets often seek rapid uptake of innovations through private and semi-public channels, whereas parts of Africa face infrastructural constraints that limit access to complex biologics. Across this region, stakeholder engagement that aligns evidence generation with local health technology assessment requirements is essential.

The Asia-Pacific region presents a mix of dynamic innovation hubs, rapidly expanding clinical research ecosystems, and variable payer systems. Some markets in this region move quickly to adopt novel therapies, supported by increasing domestic manufacturing and partnerships, while others prioritize cost containment and local value demonstration. Diagnostic accessibility and molecular testing scale-up are pivotal determinants of targeted therapy penetration, and partnerships between global manufacturers and regional distributors play a critical role in ensuring continuity of supply and post-marketing support.

Competitive dynamics for innovators, biologics manufacturers, and strategic partners emphasizing evidence depth, supply-chain resilience, and diagnostic integration in melanoma care

Competitive positioning in melanoma therapy is defined by a blend of clinical differentiation, evidentiary depth, manufacturing and supply-chain robustness, and strategic partnerships. Leading companies have invested heavily in developing combination regimens that pair immune checkpoint blockade with targeted or adjunctive agents, aiming to extend durable responses while managing toxicity. Product portfolios that include both intravenous immune agents and oral targeted therapies create strategic advantages in addressing multiple patient segments and sequencing needs, while integrated companion diagnostic programs enhance the ability to capture biomarker-defined populations.

Manufacturers that demonstrate operational excellence in biologics manufacturing, cold-chain logistics, and regulatory compliance reduce supply disruptions and boost customer confidence among health systems and payers. In addition, commercial capabilities around medical affairs, real-world evidence generation, and health economics are increasingly decisive; organizations that can rapidly generate post-approval effectiveness and safety data secure stronger reimbursement positioning. Strategic alliances with diagnostic companies, contract research organizations, and regional distribution partners expand market reach and facilitate localized launches.

Smaller biotechnology firms that focus on novel mechanisms or niche indications may become attractive acquisition targets as larger players seek to augment pipelines and diversify immuno-oncology portfolios. In this context, companies that balance scientific innovation with pragmatic go-to-market strategies-such as early payer engagement and evidence generation aligned to health technology requirements-are better positioned to convert clinical promise into sustained clinical adoption.

Actionable strategic priorities for manufacturers and stakeholders to align evidence generation, supply resilience, and commercialization for improved access and long-term therapeutic value

Industry leaders should adopt a multifaceted approach that aligns clinical development with payer evidence needs, strengthens supply resilience, and optimizes go-to-market execution to maximize patient access and therapeutic impact. First, companies must prioritize early and continuous engagement with payers and health technology assessment bodies to ensure clinical trial endpoints, quality-of-life measures, and real-world evidence plans match reimbursement expectations. Embedding health economics and outcomes research in development programs will facilitate smoother transitions from approval to routine clinical use.

Second, building supply-chain resilience is imperative. Manufacturers should evaluate diversified sourcing strategies, invest in near-shore or regional manufacturing capacity where feasible, and implement inventory and dual-sourcing arrangements for critical components. These measures reduce vulnerability to trade policy shifts and logistical disruptions, thereby protecting patient access. Third, commercial organizations must differentiate through integrated patient support programs that address adherence, toxicity management, and diagnostic coordination, enabling more predictable utilization and better patient outcomes.

Finally, strategic partnerships and data-driven commercialization tactics will accelerate uptake. Collaborations with diagnostic providers, specialty pharmacies, and clinical networks can expand testing capacity and streamline initiation of targeted therapies. Leveraging real-world data to demonstrate comparative effectiveness and long-term benefits will support formulary negotiations. By executing on these priorities, leaders can bridge innovation and access while delivering measurable value to clinicians, payers, and patients.

Comprehensive and transparent research methodology integrating primary expert interviews, regulatory and clinical literature synthesis, and pragmatic scenario analysis to ensure actionable findings

The findings presented in this report are grounded in a structured, multi-source research methodology that integrates primary stakeholder interviews, secondary literature, regulatory filings, and qualitative synthesis to ensure robustness and relevance. Primary inputs included discussions with clinicians, policy experts, payers, and industry leaders to capture evolving clinical practices, reimbursement dynamics, and operational realities. These interviews were complemented by careful review of regulatory approvals, clinical study publications, guidance documents, and diagnostic validation reports to triangulate therapeutic and mechanistic insights.

Secondary research encompassed peer-reviewed journals, health technology assessment outputs, clinical guidelines, and professional society statements to establish context for clinical adoption and standard-of-care evolution. The approach placed emphasis on mapping care pathways and distribution channels, analyzing how route of administration and channel preferences influence real-world use. Data on manufacturing and supply-chain practices were synthesized from industry reports and expert consultations to evaluate resilience strategies in the face of trade and logistics pressures.

Analytic rigor was maintained through cross-validation of qualitative themes and stress-testing of strategic implications across regional contexts. Where applicable, sensitivity analyses of supply-chain scenarios and policy developments were conducted to inform risk mitigation recommendations. The methodology emphasizes transparency in evidence sourcing and a practitioner-oriented lens to ensure that recommendations are actionable for decision-makers across R&D, commercial, and policy functions.

Executive synthesis highlighting the intersection of scientific innovation, policy pressures, and operational readiness that will determine future therapeutic impact and patient access in melanoma care

In sum, the melanoma treatment paradigm has entered an era defined by biological precision, immune modulation, and increasingly complex delivery considerations. Therapeutic innovation has expanded options for patients, necessitating more nuanced decision-making frameworks that integrate molecular diagnostics, toxicity management, and long-term survivorship planning. At the same time, external factors such as trade policy shifts and supply-chain dynamics underscore the importance of operational resilience and early payer engagement to safeguard access and maintain continuity of care.

Stakeholders across the value chain-developers, clinicians, payers, and distributors-must adopt coordinated approaches that align evidence generation with real-world needs, invest in resilient manufacturing and logistics, and deploy patient-centric support models that facilitate adherence and monitoring. Strategic partnerships with diagnostic providers and specialty channels will be critical to translating mechanistic advances into durable clinical outcomes. The convergence of scientific progress, regulatory adaptation, and commercial innovation presents opportunities to improve patient outcomes globally, provided that organizations proactively address the operational and policy challenges that accompany change.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Melanoma Drug Market, by Therapy Type

  • 8.1. Chemotherapy
  • 8.2. Immunotherapy
  • 8.3. Targeted Therapy

9. Melanoma Drug Market, by Mechanism Of Action

  • 9.1. BRAF Inhibitors
  • 9.2. Checkpoint Inhibitors
  • 9.3. MEK Inhibitors

10. Melanoma Drug Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Melanoma Drug Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Retail Pharmacies

12. Melanoma Drug Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Melanoma Drug Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Melanoma Drug Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Melanoma Drug Market

16. China Melanoma Drug Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. BioNTech SE
  • 17.7. Eisai Co., Ltd.
  • 17.8. Eli Lilly and Company
  • 17.9. F. Hoffmann-La Roche Ltd.
  • 17.10. GlaxoSmithKline PLC
  • 17.11. Hikma Pharmaceuticals PLC
  • 17.12. Merck KGaA
  • 17.13. Novartis AG
  • 17.14. Pfizer, Inc.
  • 17.15. Regeneron Pharmaceuticals Inc.
  • 17.16. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL MELANOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MELANOMA DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MELANOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MELANOMA DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MELANOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MELANOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MELANOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MELANOMA DRUG MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MELANOMA DRUG MARKET SIZE, BY BRAF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MELANOMA DRUG MARKET SIZE, BY BRAF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MELANOMA DRUG MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MELANOMA DRUG MARKET SIZE, BY MEK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MELANOMA DRUG MARKET SIZE, BY MEK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MELANOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MELANOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MELANOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MELANOMA DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MELANOMA DRUG MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MELANOMA DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MELANOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MELANOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MELANOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MELANOMA DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MELANOMA DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MELANOMA DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS MELANOMA DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. NORTH AMERICA MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. LATIN AMERICA MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. MIDDLE EAST MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. MIDDLE EAST MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 65. MIDDLE EAST MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. MIDDLE EAST MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. AFRICA MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AFRICA MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 70. AFRICA MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 71. AFRICA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MELANOMA DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. ASEAN MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASEAN MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. ASEAN MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 81. ASEAN MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 82. ASEAN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GCC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GCC MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. GCC MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 86. GCC MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. GCC MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPEAN UNION MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPEAN UNION MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPEAN UNION MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPEAN UNION MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPEAN UNION MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. BRICS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. BRICS MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. BRICS MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 96. BRICS MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. BRICS MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. G7 MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. G7 MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. G7 MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 101. G7 MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. G7 MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NATO MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NATO MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NATO MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 106. NATO MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. NATO MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. UNITED STATES MELANOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. UNITED STATES MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. UNITED STATES MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 112. UNITED STATES MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. UNITED STATES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. CHINA MELANOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. CHINA MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. CHINA MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 117. CHINA MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. CHINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)